Alnylam Pharmaceuticals Inc. (ALNY)

86.50
NASDAQ : Health Technology
Prev Close 84.60
Day Low/High 84.77 / 87.19
52 Wk Low/High 60.27 / 96.14
Avg Volume 696.30K
Exchange NASDAQ
Shares Outstanding 111.21M
Market Cap 9.41B
EPS -7.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
Over 25 Companies To Present At Emerald Groundhog Investment Forum: Thursday, February 6th

Over 25 Companies To Present At Emerald Groundhog Investment Forum: Thursday, February 6th

Pennsylvania’s famous groundhog Punxsutawney Phil may have forecast six more weeks of winter, but he’s delivering clear skies and a perfect day for the Groundhog Day Investment Forum on Thursday, February 6 th.

Alnylam To Webcast Presentation At Upcoming Investor Conferences

Alnylam To Webcast Presentation At Upcoming Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 16 th Annual BIO CEO & Investor Conference on Tuesday, ...

Investment Industry To Gather In Philadelphia At 21st Annual Groundhog Investment Forum

Investment Industry To Gather In Philadelphia At 21st Annual Groundhog Investment Forum

Emerald Asset Management, Inc. will welcome hundreds of investment industry professionals to the 21 st annual Emerald Groundhog Day Investment Forum, scheduled to be held on Thursday, February 6 th at the Radisson...

Alnylam Initiates Phase 1 Clinical Trial With ALN-AT3, A Subcutaneously Administered RNAi Therapeutic Targeting Antithrombin (AT) In Development For The Treatment Of Hemophilia And Rare Bleeding Disorders (RBD)

Alnylam Initiates Phase 1 Clinical Trial With ALN-AT3, A Subcutaneously Administered RNAi Therapeutic Targeting Antithrombin (AT) In Development For The Treatment Of Hemophilia And Rare Bleeding Disorders (RBD)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has initiated a Phase 1 study with ALN-AT3, a subcutaneously administered RNAi therapeutic targeting ...

Today's Dead Cat Bounce Stock Is Alnylam Pharmaceuticals (ALNY)

Today's Dead Cat Bounce Stock Is Alnylam Pharmaceuticals (ALNY)

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a "dead cat bounce" (down big yesterday but up big today) candidate

Alnylam Pharmaceuticals (ALNY) Highlighted As Today's Perilous Reversal Stock

Alnylam Pharmaceuticals (ALNY) Highlighted As Today's Perilous Reversal Stock

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a "perilous reversal" (up big yesterday but down big today) candidate

'Mad Money' Lightning Round: Buy, Buy, Buy Johnson Controls

'Mad Money' Lightning Round: Buy, Buy, Buy Johnson Controls

Cramer likes Whole Foods only for the long term but he's not recommending E-House China Holdings.

Jim Cramer's 'Mad Money' Recap: Is the Downturn Serious?

Jim Cramer's 'Mad Money' Recap: Is the Downturn Serious?

The markets overlooked a host of positive news today and instead focused on the negative, using the weakness as an excuse to sell everything, Cramer says.

Alnylam Pharmaceuticals Inc. (ALNY): Today's Featured Health Care Winner

Alnylam Pharmaceuticals Inc. (ALNY): Today's Featured Health Care Winner

Alnylam Pharmaceuticals was a winner within the health care sector, rising $27.07 (40.9%) to $93.28 on heavy volume

It's Lunchtime at the J.P. Morgan Healthcare Confab. Here's What I Learned So Far

It's Lunchtime at the J.P. Morgan Healthcare Confab. Here's What I Learned So Far

Here are some random thoughts and observations from what I saw and heard this morning. Totally off the cuff stuff on Celgene, InterMune, Alnylam, NPS Pharma and Seattle Genetics.

J.P. Morgan Healthcare Confab Live Blog: Day One

J.P. Morgan Healthcare Confab Live Blog: Day One

TheStreet's Adam Feuerstein is providing live coverage all week from the biotech sector's most important investor conference.

The Deal: Sanofi to Take 12% of Alnylam

The Deal: Sanofi to Take 12% of Alnylam

Sanofi expands a rare-disease alliance with Alnylam Pharmaceuticals that would leave the French drug giant with a minority Alnylam stake and access to the target's portfolio through 2020.

New Lifetime High Reached By Alnylam Pharmaceuticals (ALNY)

New Lifetime High Reached By Alnylam Pharmaceuticals (ALNY)

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a new lifetime high candidate

The J.P. Morgan Healthcare Confab Monday Morning News Dump

The J.P. Morgan Healthcare Confab Monday Morning News Dump

It's still pre-dawn in San Francisco, a few hours from the start of the J.P. Morgan Healthcare Conference, but that hasn't stopped biotech and drug companies from dumping a ton of news and announcements into the market. Here's a brief look at what's making headlines this morning:

The Deal: European Stocks Rise Slightly, Banks Get Good News

The Deal: European Stocks Rise Slightly, Banks Get Good News

The main European markets rise slightly on Monday, partly on hopes that Friday's poor U.S. jobs figures will give the Federal Reserve reason to slow its taper program over the coming months.

Genzyme And Alnylam Expand Collaboration On Rare Genetic Diseases

Genzyme And Alnylam Expand Collaboration On Rare Genetic Diseases

Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), and Alnylam Pharmaceuticals, Inc.

Alnylam And Genzyme Form Transformational Alliance For RNAi Therapeutics As Genetic Medicines

Alnylam And Genzyme Form Transformational Alliance For RNAi Therapeutics As Genetic Medicines

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, and Genzyme, a Sanofi company (EURONEXT:SAN and NYSE:SNY), announced today that they have formed a transformational alliance for ...

Alnylam Acquires Investigational RNAi Therapeutic Assets From Merck

Alnylam Acquires Investigational RNAi Therapeutic Assets From Merck

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today the acquisition of Merck’s wholly owned subsidiary Sirna Therapeutics, Inc.

Alnylam Provides Key 2014 Goals For RNAi Therapeutics Pipeline

Alnylam Provides Key 2014 Goals For RNAi Therapeutics Pipeline

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today its key “Alnylam 5x15™” pipeline goals.

The Twitterverse's Biotech Stock Picks for 2014

The Twitterverse's Biotech Stock Picks for 2014

Biotech Twitter gets a chance to predict which stocks are worth buying this year.

Alnylam To Webcast Presentation At 32nd Annual J.P. Morgan Healthcare Conference

Alnylam To Webcast Presentation At 32nd Annual J.P. Morgan Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 32 nd Annual J.

The Billion-Dollar Biotech Club: Speculation Trumped Risk

The Billion-Dollar Biotech Club: Speculation Trumped Risk

The list of biotech and drug stocks with billion-dollar market values almost doubled in 2013 -- a sign that investors loved speculation and were rewarded for it.

Alnylam Pharmaceuticals Inc. (ALNY): Today's Featured Drugs Laggard

Alnylam Pharmaceuticals Inc. (ALNY): Today's Featured Drugs Laggard

Alnylam Pharmaceuticals was a leading decliner within the drugs industry, falling $0.71 (-1.1%) to $65.73 on average volume

New Lifetime High Today: Alnylam Pharmaceuticals (ALNY)

New Lifetime High Today: Alnylam Pharmaceuticals (ALNY)

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a new lifetime high candidate

Alnylam And Collaborators Publish Novel Method For Detection Of Tissue-Specific, RNAi-Mediated Gene Silencing

Alnylam And Collaborators Publish Novel Method For Detection Of Tissue-Specific, RNAi-Mediated Gene Silencing

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the publication of a new paper describing a novel technique called circulating Extracellular RNA Detection (cERD).

Alnylam Presents New Pre-Clinical Data On Pharmacology Of GalNAc-siRNA Conjugates

Alnylam Presents New Pre-Clinical Data On Pharmacology Of GalNAc-siRNA Conjugates

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data on the pharmacology of GalNAc-siRNA conjugates at the 12 th ...

Alnylam Initiates Phase II Clinical Trial With ALN-TTRsc, A Subcutaneously Delivered RNAi Therapeutic Targeting Transthyretin (TTR) In Development For The Treatment Of TTR-Mediated Amyloidosis (ATTR)

Alnylam Initiates Phase II Clinical Trial With ALN-TTRsc, A Subcutaneously Delivered RNAi Therapeutic Targeting Transthyretin (TTR) In Development For The Treatment Of TTR-Mediated Amyloidosis (ATTR)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has initiated a pilot Phase II study with ALN-TTRsc, a subcutaneously delivered RNAi therapeutic targeting the...

Alnylam Presents New Pre-clinical Data On ALN-AT3, An RNAi Therapeutic Targeting Antithrombin (AT) For The Treatment Of Hemophilia And Rare Bleeding Disorders (RBD)

Alnylam Presents New Pre-clinical Data On ALN-AT3, An RNAi Therapeutic Targeting Antithrombin (AT) For The Treatment Of Hemophilia And Rare Bleeding Disorders (RBD)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with ALN-AT3, a subcutaneously administered RNAi therapeutic targeting ...

New Alnylam Pre-clinical Results On ALN-CC5, An RNAi Therapeutic Targeting Complement Component C5 For The Treatment Of Complement-Mediated Diseases, Demonstrate Up To 98% Serum C5 Knockdown And Up To 94% Inhibition Of Hemolytic Activity In Non-Human Primates

New Alnylam Pre-clinical Results On ALN-CC5, An RNAi Therapeutic Targeting Complement Component C5 For The Treatment Of Complement-Mediated Diseases, Demonstrate Up To 98% Serum C5 Knockdown And Up To 94% Inhibition Of Hemolytic Activity In Non-Human Primates

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with ALN-CC5, a subcutaneously administered RNAi therapeutic targeting ...

Best Biotech CEO of 2013: Your Vote Counts

Best Biotech CEO of 2013: Your Vote Counts

The CEOs from NPS Pharma, Onyx Pharma, Bristol-Myers Squibb, Celgene and Ligand Pharma vie for the coveted title of Best Biotech CEO.